The approach was studied in the Nature Portfolio of journals’ npj Parkinson’s Disease. It outlines the medtech giant’s adaptive DBS algorithm for personalized therapy in Parkinson’s disease (ADAPT-PD). The global, multi-center, prospective, single-blind, randomized crossover study looks at the safety and effectiveness of chronic dual and single threshold aDBS models as compared to continuous DBS across all Parkinson’s patients eligible for DBS.

Medtronic said the study remains ongoing as the largest, longest assessment of aDBS in an at-home setting. To date, the company reports 68 participants with either subthalamic nucleus or globus pallidus internus DBS connected to a Percept PC neurostimulator.